265
Views
3
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada

ORCID Icon, , , , , , , , & show all
Pages 1356-1363 | Received 13 May 2017, Accepted 27 Sep 2017, Published online: 16 Oct 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

María Elena Cabrera, Neda Marinov, Macarena Roa, Jorge J. Castillo & Estella Matutes. (2022) Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile. Leukemia & Lymphoma 63:5, pages 1137-1143.
Read now
Rudolf Weide, Stefan Feiten, Geothy Chakupurakal, Vera Friesenhahn, Kristina Kleboth, Hubert Köppler, Julia Lutschkin, Christoph van Roye, Jörg Thomalla & Jochen Heymanns. (2020) Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Leukemia & Lymphoma 61:3, pages 557-566.
Read now
Lina van der Straten, Avinash G. Dinmohamed, Peter E. Westerweel, Anton W. Langerak, Jurgen Riedl, Jeanette K. Doorduijn, Arnon P. Kater & Mark-David Levin. (2018) Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. Leukemia & Lymphoma 59:11, pages 2757-2761.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.